A Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic Prophylaxis (Efa Emi Bone Health Study)
Part of paid clinical trials in Little Rock, Arkansas.
- Sponsor
- Arkansas Children's Hospital Research Institute
- Study ID
- NCT07582276
- Status
- Recruiting
Conditions
- Hemophilia a
Eligibility Criteria
- Sex
- MALE
- Age
- 30 Years - 50 Years
- Healthy Volunteers
- Not accepted
Study Details
This study will compare bone mineral density in patients with severe hemophilia A receiving prophylaxis with emicizumab or efanesoctocog alfa. Participants will undergo assessments of bone mineral density, bone remodeling biomarkers, thrombin generation, plasmin generation, and joint health over a five-year period. The study aims to evaluate whether differences in prophylactic therapy are associated with differences in bone health outcomes.
Key Dates
- First listed
- May 12, 2026
- Start date
- Sep 21, 2026
- Status verified
- Oct 2026
- Primary completion
- Sep 30, 2031
- Completion
- Sep 30, 2032
Study Design
- Enrollment
- 50 participants (estimated)
Arms
- Arm: Patients with Severe Hemophilia A on Efanesoctocog alfa prophylaxisParticipants with severe hemophilia A receiving prophylaxis with efanesoctocog alfa as part of routine clinical care. Participants will undergo longitudinal assessments of bone mineral density, bone remodeling biomarkers, thrombin generation, plasmin generation, and joint health over a five-year period.
- Arm: Patients with Severe Hemophilia A on Emicizumab prophylaxisParticipants with severe hemophilia A receiving prophylaxis with emicizumab as part of routine clinical care. Participants will undergo longitudinal assessments of bone mineral density, bone remodeling biomarkers, thrombin generation, plasmin generation, and joint health over a five-year period.
Primary Outcome Measure
Longitudinal change in femoral neck bone mineral density (g/cm²) [ Time Frame: Baseline and annually through 5 years. ]
Central Contacts
- Carol D Pierce, RN501-364-4440
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Arkansas Children's | Little Rock | Arkansas | 72202 | - |
Find similar trials in Little Rock, AR
By research site
Related Studies
- ASC618 Gene Therapy in Hemophilia A PatientsPHASE1/PHASE2 · Recruiting · ASC Therapeutics · Little Rock, Arkansas
- Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab ProphylaxisRecruiting · Wayne State University · Little Rock, Arkansas
- Treatment of Hemophilia A Patients With FVIII InhibitorsRecruiting · Emory University · Atlanta, Georgia
- SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisPHASE3 · Recruiting · Emory University · Atlanta, Georgia